Quick Takeaways
- PRAX - Praxis Precision Medicines, Inc. has 19 insiders with reported activity on this page.
- Net insider value flow over the last year: +$25,733,624.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 19 Insiders of Praxis Precision Medicines, Inc.
- Symbol
- PRAX on Nasdaq
- Location
- Boston, MA
What Changed
- Buy value: $33,198,124; sell value: $7,464,499.
- Net share flow: +275,180.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$25,733,624.
Buys
$33,198,124
Shares: 313,910
Insiders: 1
Sells
$7,464,499
Shares: 38,730
Insiders: 2
Net
+$25,733,624
Shares: +275,180
Insiders: -1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 313,910 | 38,730 | $33,198,124 | $7,464,499 | +$25,733,624 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Praxis Precision Medicines, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Adage Capital Management, L.P. | 10%+ Owner | $288,424,500 | +$33,198,124 | +13% | Filing P/S | 16 Oct 2025 |
| Clarus Lifesciences III, L.P. | 10%+ Owner | $123,282,606 | Mixed | 12 May 2021 | ||
| Marcio Souza | Chief Executive Officer, Director | $22,945,243 | Mixed | 08 Jan 2026 | ||
| Timothy Edwin Kelly | Chief Financial Officer | $8,560,624 | Mixed | 12 Jan 2026 | ||
| Megan Sniecinski | Chief Operating Officer | $7,866,862 | Mixed | 12 Jan 2026 | ||
| Alex Nemiroff | General Counsel and Secretary | $7,150,673 | -$4,852,256 | -40% | Mixed | 12 Jan 2026 |
| Lauren Mastrocola | Principal Accounting Officer | $3,707,505 | -$2,612,244 | -41% | Mixed | 12 Jan 2026 |
| Nicole Sweeny | Chief Commercial Officer | $972,813 | Mixed | 12 Feb 2023 | ||
| Dean J. Mitchell | Director | $759,734 | Mixed | 24 Sep 2025 | ||
| Stuart A. Arbuckle | Director | $336,332 | Mixed | 06 Feb 2026 | ||
| Jeffrey B. Kindler | Director | $336,332 | Mixed | 06 Feb 2026 | ||
| BSOF Parallel Master Fund L.P. | 10%+ Owner | $0 | Mixed | 06 Oct 2021 | ||
| Merit Ester Cudkowicz | Director | Mixed | 26 Jun 2025 | |||
| Bernard Ravina | Chief Medical Officer | Mixed | 22 Jun 2022 | |||
| Jeffrey Chodakewitz | Director | Mixed | 26 Jun 2025 | |||
| Gregory Norden | Director | Mixed | 26 Jun 2025 | |||
| Jill DeSimone | Director | Mixed | 26 Jun 2025 | |||
| Stefan Vitorovic | Director | Mixed | 26 May 2022 | |||
| William D. Young | Director | Mixed | 26 Jun 2025 |
Top shareholders of Praxis Precision Medicines, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13F
13D/G
|
Company |
12%
from 13D/G
|
3,240,086
|
$954,833,974 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
8.1%
|
2,078,500
|
$612,617,092 | — | 31 Dec 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
|
Company |
7.2%
from 13D/G
|
1,995,986
|
$588,296,914 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Steven A. Cohen · Company |
6.1%
|
1,569,309
|
$452,667,181 | -$145,274,958 | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.7%
|
1,460,933
|
$430,595,392 | — | 31 Dec 2025 | |
| FMR LLC |
13F
13D/G
|
Company |
5.4%
from 13D/G
|
1,358,675
|
$400,455,884 | — | 31 Dec 2025 | |
| Orbis Allan Gray Ltd |
13F
|
Company |
4.9%
|
1,255,162
|
$369,946,448 | — | 31 Dec 2025 | |
| ORBIS INVESTMENT MANAGEMENT LTD |
13D/G
|
— |
5%
|
1,252,573
|
$361,304,682 | $0 | 31 Dec 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
4.4%
|
1,126,488
|
$332,021,073 | — | 31 Dec 2025 | |
| Adage Capital Management, L.P. |
3/4/5
13D/G
|
10%+ Owner |
3.8%
from 13D/G
|
4,434,260
mixed-class rows
|
$288,424,500 | +$33,198,124 | 16 Oct 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
3.8%
|
965,313
|
$284,516,354 | — | 31 Dec 2025 | |
| Cormorant Asset Management, LP |
13F
13D/G
|
Company |
4%
from 13D/G
|
950,000
|
$280,003,000 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.6%
|
933,061
|
$275,010,399 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
3.5%
|
903,351
|
$266,253,674 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
13D/G
|
Company |
2.9%
from 13D/G
|
889,889
|
$262,286,289 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.4%
|
882,215
|
$260,024,049 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
|
Company · T. Rowe Price Associates, Inc. |
4.8%
from 13D/G
|
785,987
|
$231,662,000 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2.8%
|
716,184
|
$211,088,072 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
562,379
|
$165,783,193 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
2.1%
|
530,751
|
$156,433,549 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
2%
|
522,763
|
$154,079,168 | — | 31 Dec 2025 | |
| Clarus Lifesciences III, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,894,109
|
$123,282,606 | — | 12 May 2021 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
1.6%
|
408,787
|
$120,485,880 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13F
|
Company |
1.5%
|
375,000
|
$110,527,500 | — | 31 Dec 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
1.5%
|
373,787
|
$110,169,980 | — | 31 Dec 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.4%
|
362,966
|
$106,980,599 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.4%
|
356,074
|
$104,949,253 | — | 31 Dec 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
1.3%
|
328,895
|
$96,938,512 | — | 31 Dec 2025 | |
| Hood River Capital Management LLC |
13F
|
Company |
1.1%
|
289,467
|
$85,317,504 | — | 31 Dec 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1.1%
|
276,392
|
$81,464,000 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.94%
|
240,588
|
$71,085,242 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.77%
|
198,301
|
$58,447,237 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.75%
|
192,284
|
$56,673,786 | — | 31 Dec 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.72%
|
185,000
|
$54,526,900 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.69%
|
176,562
|
$52,039,884 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.66%
|
168,897
|
$49,780,702 | — | 31 Dec 2025 | |
| Soleus Capital Master Fund, L.P. |
13D/G
|
— |
4.6%
|
966,740
|
$40,651,514 | -$2,144,555 | 30 Jun 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.52%
|
134,992
|
$39,787,542 | — | 31 Dec 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
4.9%
|
1,016,497
|
$37,813,688 | -$6,466,960 | 31 Mar 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.49%
|
125,722
|
$37,055,302 | — | 31 Dec 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.43%
|
110,590
|
$32,596,684 | — | 31 Dec 2025 | |
| Capital Research Global Investors |
13D/G
|
— |
4.2%
|
853,746
|
$31,759,351 | $0 | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.41%
|
105,412
|
$31,069,133 | — | 31 Dec 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
0.39%
|
100,781
|
$29,704,192 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.37%
|
94,500
|
$27,852,930 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.35%
|
89,200
|
$26,290,808 | — | 31 Dec 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.34%
|
88,704
|
$26,144,616 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.34%
|
86,581
|
$25,518,884 | — | 31 Dec 2025 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.32%
|
83,036
|
$24,474,031 | — | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.32%
|
82,465
|
$24,305,734 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Praxis Precision Medicines, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Stuart A. Arbuckle | PRAX | Common Stock | Award | 1,166 | 1,166 | 06 Feb 2026 | Direct | |||
| Stuart A. Arbuckle | PRAX | Stock Option (Right to Buy) | Award | 224 | 224 | 06 Feb 2026 | Direct | |||
| Jeffrey B. Kindler | PRAX | Common Stock | Award | 1,166 | 1,166 | 06 Feb 2026 | Direct | |||
| Jeffrey B. Kindler | PRAX | Stock Option (Right to Buy) | Award | 224 | 224 | 06 Feb 2026 | Direct | |||
| Lauren Mastrocola | PRAX | Common Stock | Tax liability | -2.49% | -344 | 13,446 | 12 Jan 2026 | Direct | ||
| Megan Sniecinski | PRAX | Common Stock | Tax liability | -3.01% | -885 | 28,530 | 12 Jan 2026 | Direct | ||
| Alex Nemiroff | PRAX | Common Stock | Tax liability | -2.88% | -768 | 25,933 | 12 Jan 2026 | Direct | ||
| Timothy Edwin Kelly | PRAX | Common Stock | Tax liability | -2.95% | -943 | 31,046 | 12 Jan 2026 | Direct | ||
| Lauren Mastrocola | PRAX | Common Stock | Tax liability | -2.59% | -367 | 13,790 | 10 Jan 2026 | Direct | ||
| Megan Sniecinski | PRAX | Common Stock | Tax liability | -3.56% | -1,087 | 29,415 | 10 Jan 2026 | Direct | ||
| Alex Nemiroff | PRAX | Common Stock | Tax liability | -3.32% | -917 | 26,701 | 10 Jan 2026 | Direct | ||
| Timothy Edwin Kelly | PRAX | Common Stock | Tax liability | -4.01% | -1,335 | 31,989 | 10 Jan 2026 | Direct | ||
| Marcio Souza | PRAX | Common Stock | Tax liability | -5.24% | -4,252 | 76,890 | 10 Jan 2026 | Direct | ||
| Lauren Mastrocola | PRAX | Common Stock | Award | 36% | 3,750 | 14,157 | 08 Jan 2026 | Direct | ||
| Lauren Mastrocola | PRAX | Stock Option (Right to Buy) | Award | 7,500 | 7,500 | 08 Jan 2026 | Direct | |||
| Megan Sniecinski | PRAX | Common Stock | Award | 46.1% | 9,625 | 30,502 | 08 Jan 2026 | Direct | ||
| Megan Sniecinski | PRAX | Stock Option (Right to Buy) | Award | 7,700 | 7,700 | 08 Jan 2026 | Direct | |||
| Alex Nemiroff | PRAX | Common Stock | Award | 33.1% | 6,875 | 27,618 | 08 Jan 2026 | Direct | ||
| Alex Nemiroff | PRAX | Stock Option (Right to Buy) | Award | 5,500 | 5,500 | 08 Jan 2026 | Direct | |||
| Timothy Edwin Kelly | PRAX | Common Stock | Award | 35.9% | 8,800 | 33,324 | 08 Jan 2026 | Direct | ||
| Timothy Edwin Kelly | PRAX | Stock Option (Right to Buy) | Award | 7,040 | 7,040 | 08 Jan 2026 | Direct | |||
| Marcio Souza | PRAX | Common Stock | Award | 51.7% | 27,640 | 81,142 | 08 Jan 2026 | Direct | ||
| Marcio Souza | PRAX | Stock Option (Right to Buy) | Award | 22,110 | 22,110 | 08 Jan 2026 | Direct | |||
| Lauren Mastrocola | PRAX | Common Stock | Tax liability | -0.34% | -35 | 10,407 | 07 Jan 2026 | Direct | ||
| Alex Nemiroff | PRAX | Common Stock | Tax liability | -0.43% | -89 | 20,743 | 07 Jan 2026 | Direct | ||
| Timothy Edwin Kelly | PRAX | Common Stock | Tax liability | -0.56% | -139 | 24,524 | 07 Jan 2026 | Direct | ||
| Marcio Souza | PRAX | Common Stock | Tax liability | -0.75% | -405 | 53,502 | 07 Jan 2026 | Direct | ||
| Marcio Souza | PRAX | Common Stock | Gift | -13.3% | -400 | 2,600 | 30 Dec 2025 | Held by spouse | ||
| Alex Nemiroff | PRAX | Common Stock | Sale | -54.7% | $4,852,256 | $193.09 | -25,130 | 20,832 | 20 Nov 2025 | Direct |
| Alex Nemiroff | PRAX | Common Stock | Options Exercise | 120.6% | 25,130 | 45,962 | 20 Nov 2025 | Direct | ||
| Alex Nemiroff | PRAX | Stock Option (Right to Buy) | Options Exercise | -100% | -25,130 | 0 | 20 Nov 2025 | Direct | ||
| Lauren Mastrocola | PRAX | Common Stock | Sale | -56.6% | $2,612,244 | $192.08 | -13,600 | 10,442 | 20 Nov 2025 | Direct |
| Lauren Mastrocola | PRAX | Common Stock | Options Exercise | 130.2% | 13,600 | 24,042 | 20 Nov 2025 | Direct | ||
| Lauren Mastrocola | PRAX | Stock Option (Right to Buy) | Options Exercise | -100% | -13,600 | 0 | 20 Nov 2025 | Direct | ||
| Timothy Edwin Kelly | PRAX | Common Stock | Award | 1.58% | 384 | 24,663 | 14 Nov 2025 | Direct | ||
| Adage Capital Management, L.P. | PRAX | Common Stock | Sale | 14.6% | $32,064,092 | $106.42 | 301,310 | 2,361,038 | 16 Oct 2025 | See footnotes |
| Adage Capital Management, L.P. | PRAX | Common Stock, $0.0001 par value per share ("Common Stock") | Sale | 0.54% | $1,134,032 | $90.00 | 12,600 | 2,361,485 | 16 Oct 2025 | See footnotes |
| Dean J. Mitchell | PRAX | Common Stock | Options Exercise | 245% | 12,251 | 17,251 | 24 Sep 2025 | Direct | ||
| Dean J. Mitchell | PRAX | Stock Option (Right to Buy) | Options Exercise | -100% | -12,251 | 0 | 24 Sep 2025 | Direct | ||
| Dean J. Mitchell | PRAX | Stock Option (Right to Buy) | Award | 10,520 | 10,520 | 26 Jun 2025 | Direct | |||
| William D. Young | PRAX | Stock Option (Right to Buy) | Award | 10,520 | 10,520 | 26 Jun 2025 | Direct | |||
| Gregory Norden | PRAX | Stock Option (Right to Buy) | Award | 10,520 | 10,520 | 26 Jun 2025 | Direct | |||
| Jill DeSimone | PRAX | Stock Option (Right to Buy) | Award | 10,520 | 10,520 | 26 Jun 2025 | Direct | |||
| Jeffrey Chodakewitz | PRAX | Stock Option (Right to Buy) | Award | 10,520 | 10,520 | 26 Jun 2025 | Direct | |||
| Merit Ester Cudkowicz | PRAX | Stock Option (Right to Buy) | Award | 10,520 | 10,520 | 26 Jun 2025 | Direct | |||
| Marcio Souza | PRAX | Common Stock | Award | 0.65% | 348 | 53,907 | 14 May 2025 | Direct | ||
| Timothy Edwin Kelly | PRAX | Common Stock | Award | 1.04% | 249 | 24,279 | 14 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.